Differential enhancement of HLA-B27 by interferon.
To further examine the role of the HLA-B27 antigen in the pathogenesis of disorders such as anterior uveitis and ankylosing spondylitis, we have measured the level of enhancement of this antigen on peripheral blood lymphocytes and compared it with that of the class I HLA antigens HLA-A2 and HLA-B7 following interferon treatment. We found that the level of enhancement of HLA-B7 was greater than that of HLA-A2 or -B7 following treatment by alpha or gamma interferon (p less than 0.002). Similarly, the level of enhancement of HLA-B7 was greater than that of HLA-A2 (p less than 0.002) (Mann Whitney U-test). A differential enhancement of HLA-B27 by lymphokines may be important in the pathogenesis of HLA-B27-related disorders.
Abi-Hanna
D
D
School of Pathology, University of New South Wales, Kensington, Australia.
Wakefield
D
D
D005805:Genes, MHC Class I / Q000187:drug effects; D008040:Genetic Linkage; D015789:HLA-A2 Antigen / Q000096:biosynthesis; D015796:HLA-B27 Antigen / Q000096:biosynthesis* / Q000235:genetics; D015793:HLA-B7 Antigen / Q000096:biosynthesis; D006801:Humans; D066298:In Vitro Techniques; D007372:Interferons / Q000494:pharmacology*; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D013167:Spondylitis, Ankylosing / Q000235:genetics / Q000276:immunology; D014606:Uveitis, Anterior / Q000235:genetics / Q000276:immunology
D015789:HLA-A2 Antigen; D015796:HLA-B27 Antigen; D015793:HLA-B7 Antigen; D007372:Interferons